The observed changes in immune parameters (reduction of Tregs, increase in CD8+ T cells, HLA DR+CD3+ cells and PSA-specific CD8+ cells) fit into the concept that successful cancer immunotherapy should not increase the percentage of regulatory T cells and should lead to the establishment of a long-term tumor cell-specific immunity [45]. This evidence concerns the gene CD8A and neoplasm.